
Beyond The Paper Gown Podcast Women’s Health Innovation Isn’t Niche — This Report Proves It
10 snips
Feb 27, 2026 Anna Jeter, co-founder and Chief Regulatory Officer of AOA Dx who works on early ovarian cancer detection, discusses the Women's Health Exits report. She talks about diagnostic delays, AOA Dx’s clinical progress and FDA discussions. The report’s data-driven case reframes fundraising, shows recent exit momentum, and explains how scaled exits expand access and patient impact.
AI Snips
Chapters
Transcript
Episode notes
AOA Dx Focuses On Faster Ovarian Diagnosis
- Anna described AOA Dx's mission: a diagnostic to triage symptomatic women faster to detect ovarian cancer earlier.
- They finished a large US clinical trial and are in active discussions with the FDA.
Women's Health Already Has Proven Exits
- Women’s health has a mature track record of meaningful exits dating back to 2000, not an unproven niche.
- Anna Jeter and team built a strict public-data database to reclassify legacy exits as women’s health and show real returns.
Dinner Sparked The Report Idea
- Anna and Oriana realized at dinner they could name many big women's health exits from memory, contradicting investor claims there's been none.
- Their firsthand experience included being part of Dijene's $1.6B HPV screening acquisition era.

